Ganesh Sathe speaks to Izzy Scott-Moncrieff in the run up to the upcoming RNA-Seq 2013 summit,18th -20th June 2013, Boston, MA
Dr. Ganesh Sathe was instrumental in forming various technology groups including DNA synthesis, mouse-genotyping, DNA/ protein sequencing, microarray, gene synthesis etc at GlaxoSmithKline (GSK). Ganesh continues to work as a manger of DNA sequencing and Transcriptomics technologies at GSK and contributes to drug discovery and development.
What initially attracted you to RNA-Seq?
RNA-Seq gives us the complete gene expression profile per given sample, and therefore the ability to capture data from the entire transcriptome.
RNA-seq provides researchers several advantages over microarray assays: firstly, measuring expression by RNA-seq is a quantitative process because actual cDNA fragments are counted. Microarrays rely on an analog to digital signal conversion of a hybridization signal to measure expression.
The second reason is due to recent developments in platforms like that from Illumina, which give researchers the ability to perform RNA-Seq on hundreds of samples in parallel, thereby decreasing the cost-per-sample of RNA-seq significantly. In fact, with current technology and chemistries, RNA-seq already costs less per sample than a microarray.
Download a PDF of the entire interview at – http://rna-seqsummit.com/library